Danaher Corporation vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Danaher Corporation trades at $207 (market cap $147.18B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.68. The key difference: Danaher Corporation pays a 0.76% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Danaher Corporation is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| DHR | VTIP | |
|---|---|---|
Market Cap | $147.18B | — |
Sector | Health | — |
52-Week High | $242.05 | $50.75 |
52-Week Low | $161.91 | $49.39 |
Enterprise Value | $169.39B | — |
Dividend Yield | 0.76% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.67, up 0.08% with a bullish technical signal. The ETF focuses on short-term Treasury Inflation-Protected Securities, offering inflation hedging. Recent news highlights institutional buying and inflation concerns, with a dividend declared for July 2026. Technical indicators show mixed signals but overall positive momentum.
Outlook: VTIP provides inflation protection amid rising prices, with potential returns around 3.8% based on current inflation. Risks include interest rate volatility and Fed policy uncertainty. It suits investors seeking low-duration, inflation-linked income, but may underperform if inflation subsides unexpectedly.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →